8 (d).)

Fig 3. Immunoblot analysis using the recombinant NC16A and C-terminal domains of COL17, the 120-kDa soluble ectodomain of COL17 and purified laminin-332

(a) The recombinant NC16A-COL17 and GST fusion protein (lane 1: control bullous pemphigoid (BP) IgG; lane 2: the patient's IgG). Circulating IgG autoantibodies reacted with NC16A-COL17 (arrow).

(b) BP915-COL17 (the recombinant protein of the C-terminal domain of COL17 amino acids spanning 1227 to 1532) and the GST fusion protein (lane 1: control BP IgG; lane 2: the patient's IgG). IgG against the C-terminal domain of COL17 was detected (arrow).

(c) The 120-kDa soluble ectodomain of COL17 (lane 1: control BP IgG; lane 2: the patient's IgG).

(d) The purified laminin-332 (lane 1: ponceau S stain sample; lane 2: the patient's IgG; lane 3: the patient's IgA). Both IgG and IgA from the patient reacted with the 105-kDa, γ2 subunit of laminin-332 (arrow).

Lichen Planus in Childhood Showing Various Cutaneous Features

Yohei Hamade[1], Ken Arita[1], Ellen Toyonaga[1], Nao Saito[1], Daisuke Inokuma[1], Kokichi Hamasaka[2] and Hiroshi Shimizu[1]
[1]Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638 and [2]Sapporo City, Japan.
E-mail: hinhira@yahoo.co.jp
Accepted August 17, 2011.

Lichen planus (LP) in childhood is less common than in adulthood, with cases in individuals under 14 years of age estimated to account for no more than 10% of cases of LP (1). We describe here a child with LP who showed various cutaneous presentations.

CASE REPORT

A 5-year-old boy presented with papules on his right leg lasting for 6 months, which had gradually progressed to his trunk and extremities. He had a history of cytomegalovirus (CMV) hepatitis. His general condition was good and he was not taking any medications. On physical examination, keratotic papules and plaques with a peachblow-colour were observed on his legs. On the right leg, the papules were arranged linearly (Fig. 1a). On the dorsum of the right foot, hyperkeratosis and hypertrophy of the eruptions was conspicuous, showing a verrucous appearance (Fig. 1b). Miliary, lustrous eruptions were scattered on his abdomen, most of which were folliculo-centred (Fig. 1c). The oral mucosae and nails were normal.

Blood tests showed a small number of atypical lymphocytes (1% of 5,200/mm^3 white blood cells (WBC)) and liver dysfunction (aspartate transaminase (AST) 99 IU/l, alanine transaminase (ALT) 80 IU/l). Cytomegalovirus-immunoglobulin G (CMV-IgG) and antibodies for Epstein-Barr (EB) virus (EB nuclear antigen (EBNA)-IgG and viral capsid antigen (VCA)-IgG) were positive, although CMV-IgM and VCA-IgM were negative. Antibodies for the hepatitis B virus (HBV) and the hepatitis C virus (HCV) were negative.

Histopathological examination of a skin biopsy specimen taken from a verrucous papule on the dorsum of the right foot showed epidermal ortho-hyperkeratosis, wedge-shaped hypergranulosis, serrated change in the epidermal rete ridge, and band-like infiltration of lymphocytes in the superficial dermis. In addition to above-mentioned features, a skin biopsy specimen taken from a papule on the abdomen showed marked vacuolar degeneration of the epidermis and many Civatte bodies.

DISCUSSION

This case presented various clinical phenotypes of LP, including linear LP, hypertrophic LP and follicular LP. Linear LP and hypertrophic LP each has been reported as accounting for 10% of cases of childhood LP, and follicular LP as accounting for approximately 4% of cases of childhood LP (2). Linear LP is less common in adult (< 1% of all LP) (2) and is considered a characteristic feature of childhood LP. The simultaneous existence of different phenotypes of LP in a single patient has been reported in several papers (3); however, to our knowledge, no report has shown simultaneous presentation of linear, hypertrophic and follicular LP, which were shown in our case.

LP is often induced by drugs, dental metals, chronic liver disease, viral infection, etc. The association of HBV or HCV infection with LP has been given particular focus (4). In this case, laboratory data of liver dysfunction together with the finding of atypical lymphocytes suggested the reactivation of EBV or CMV, which might be related to the aetiology of the LP.

Topical tacrolimus was applied as a treatment, and the eruptions gradually subsided within 6 months. Several reports have shown the usefulness of topical tacrolimus against LP, especially against LP in the oral cavity (5). This case showed a favourable clinical course during the topical treatment with tacrolimus.



Fig. 1. Clinical appearance of (a) linear keratotic papules and plaques on the right leg and (b) verrucous plaque on the dorsum of the right foot. (c) Miliary, lustrous papules distributed almost consistently with hair follicles on the abdomen.

The authors declare no conflicts of interest.

 doi: 10.2340/00015555-1260
 ISSN 0001-5555

REFERENCES

1. Kumar V, Garg BR, Baruah MC, Vasireddi SS. Childhood lichen planus (LP). J Dermatol 1993; 20: 175–177.
2. Handa S, Sahoo B. Childhood lichen planus: a study of 87 cases. Int J Dermatol 2002; 41: 423–427.
3. Kanwar AJ, De D. Lichen planus in childhood: report of 100 cases. Clin Exp Dermatol 2010; 35: 257–262.
4. Rebora A, Robert E, Rongioletti F. Clinical and laboratory presentation of lichen planus patients with chronic liver disease. J Dermatol Sci 1992; 4: 38–41.
5. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999; 140: 338–342.

C E D | 4 3 1 2 | B
Journal Name | Manuscript No.
Dispatch: 16.12.11 | Journal: CED | CE: Gayathri J.
Author Received: | No. of pages: 7 | PE: Radhika

Experimental dermatology • Original article

CED
Clinical and Experimental Dermatology

Conversion from human haematopoietic stem cells to keratinocytes requires keratinocyte secretory factors

Y. Fujita, D. Inokuma, R. Abe, M. Sasaki, H. Nakamura, T. Shimizu* and H. Shimizu

*Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; and *Department of Dermatology, Faculty of Medicine, University of Toyama, Toyama, Japan*

doi:10.1111/j.1365-2230.2011.04312.x

Summary

Background. Recent studies have reported that bone-marrow-derived stem cells (BMSCs), including haematopoietic stem cells (HSCs) and mesenchymal stromal cells, differentiate in order to regenerate various cellular lineages. Based on these findings, it is known that BMSCs can be used clinically to treat various disorders, such as myocardial infarction and neurotraumatic injuries. However, the mechanisms of HSC conversion into organ cells are incompletely understood. The mechanism is suspected to involve direct cell–cell interaction between BMSCs, damaged organ cells, and paracrine-regulated soluble factors from the organ, but to date there have been no investigations into which of these are essential for keratinocyte differentiation from HSCs.

Aim. We tried to elucidate the mechanism and necessary conditions for HSC differentiation into keratinocytes *in vitro*.

Methods. We cultured human (h)HSCs under various conditions to try to elucidate the mechanism and necessary conditions for hHSCs to differentiate into keratinocytes.

Result. hHSCs cocultured with mouse keratinocytes induced expression of human keratin 14 and transglutaminase I. Only 0.1% of the differentiated keratinocytes possessed multiple nuclei indicating cell fusion. Coculture of hHSCs with fixed murine keratinocytes (predicted to stabilize cellular components) failed to induce conversion into keratinocytes. Conversely, keratinocyte-conditioned medium from both human and mouse keratinocytes was found to mediate hHSC conversion into keratinocytes.

Conclusions. Human HSCs are capable of differentiation into keratinocytes, and cell fusion is extremely rare. This differentiation is mediated by the plasma environment rather than by direct cell–cell interactions.

Introduction

Recent studies have reported that bone marrow-derived stem cells (BMSCs), including haematopoietic stem cells (HSCs) and multipotent mesenchymal stromal cells (MSCs), differentiate into various cellular lineages.[1–3] Based on these findings, BMSCs have been used to treat several disorders in animal models, including myocardial infarction, Parkinson's disease and neurotraumatic injuries.[4–6] We previously used a murine bone-marrow transplantation model to show that HSCs can differentiate into functional keratinocytes *in vivo*.[7,8] Cutaneous T-cell-attracting chemokine (CTACK)/CCL27 was found to be the major regulator involved in the migration from bone marrow of keratinocyte precursor cells, which expressed CCR10, the receptor for the CTACK ligand.[7] In addition, we reported that bone marrow-derived MSCs also convert into keratin14-positive keratinocytes *in vivo* and *in vitro*.[9]

Correspondence: Dr Yasuyuki Fujita, Department of Dermatology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan
E-mail: yfujita@med.hokudai.ac.jp

The first two authors contributed equally to this work, and should be considered joint first authors.

Conflict of interest: none declared.

Accepted for publication 8 October 2011

The factor or mechanism governing the differentiation of HSCs into injured organ cells is been fully understood. Possible mechanisms include direct cell–cell interaction between peripheral haematopoietic progenitor cells and damaged organ cells, and involvement of paracrine-regulated soluble factors from the organ. Requirement of feeder cells such as 3T3 cells when culturing keratinocytes implies that direct cellular interactions play a major role in keratinocyte differentiation, proliferation and homeostasis. Previous papers have reported that use of secretory factors from damaged liver tissue enables HSCs to take on many characteristics of liver cells.[10]

We cultured human (h)HSCs under various conditions to elucidate the mechanism and necessary conditions of hHSC differentiation into keratinocytes.

Methods

The study was approved by the ethics committee of Hokkaido University Graduate School of Medicine, and volunteers signed consent forms approved by the Hokkaido University Graduate School of Medicine and the Hokkaido Red Cross Blood Centre Committee for the Protection of Human Subjects.[11] All animal procedures were conducted according to guidelines provided by the Hokkaido University Institutional Animal Care and Use Committee under an approved protocol.

Cells

Human peripheral blood CD34-positive cells, which are considered to be hHSCs, were collected. Recombinant human granulocyte colony-stimulating factor (G-CSF; Chugai Pharmaceutical Co. and Kyowa Hakko Pharmaceutical Co., Tokyo, Japan) was administered to the healthy subjects. Mobilized hHSCs were then isolated from peripheral blood using immunomagnetic beads with an antibody against CD34 as described previously.[11,12]

Pam 212, a murine keratinocyte cell line, was derived from spontaneously transformed BALB/c keratinocytes. Murine dermal fibroblasts were obtained from the dorsal skin surface of C57BL/6 mice. Normal human epidermal keratinocytes (NHEKs; Cambrex, East Rutherford, NJ, USA) were used as controls.

Coculture of hHSCs

To distinguish the differentiated HSC-derived keratinocytes and cocultured keratinocytes, we chose hHSCs and murine keratinocytes Pam 212 to coculture. PAM 212 and murine dermal fibroblasts were grown separately on eight-well culture slides to 80% confluence in DMEM (Invitrogen, Grand Island, NY, USA), and NHEKs were grown in Konjac glucomannan medium (KGM, Lonza Walkersville, Walkersville, MD, USA). Each cell was washed twice with phosphate-buffered saline (PBS) and then 1×10^5 hHSCs were added to each well and cocultured for 5 days in RPMI medium (Invitrogen). Each experiment was repeated three times.

Paraformaldehyde fixation of keratinocytes

In coculture with fixed cells, Pam 212 cells or NHEKs were grown on eight-well culture slides to 80% confluence, and then fixed with 0.5% paraformaldehyde for 15 min at 25 °C. Each well was washed twice with PBS, and 1×10^5 hHSCs per well were cultured with fixed keratinocytes for 5 days with RPMI.

Preparation of conditioned medium

Pam 212 cells or NHEKs at 80% confluence were washed twice with PBS, and cultured for 48 h with RPMI. The conditioned media were centrifuged at 2500 ***g*** for 10 min, filtered through 0.22-μm filters (Millipore, Bedford, MA, USA), and stored at − 80 °C until use. These conditioned media were then used to culture 1×10^5 hHSCs on eight-well culture slides with the conditioned media collected from the Pam 212 cells or NHEKs.

Culture with secreted factors

The hHSCs (1×10^5) were plated onto eight-well slides as before, and cultured in keratinocyte basal medium (Invitrogen) containing 0.5 nmol/L bone morphogenetic protein-4 (R&D Systems, Minneapolis, MN, USA), keratinocyte growth factor (KGF; Invitrogen) or interleukin-1-induced growth factor (IGF; Invitrogen). After 48 h of culture, hHSCs were stained to investigate their differentiation into keratinocytes.

Immunocytochemistry

Skin samples were embedded in optimal cutting temperature compound (Sakura Finetek Japan, Tokyo, Japan), then cut on a cryostat into 5 μm sections, which were placed onto microscope slides. The slides were used for indirect immunofluorescence using the following primary antibodies were used: human cytokeratin (CK)5 (catalogue no. RCK103) and human CK14 (LL002) (both Santa Cruz Biotechnology, Santa Cruz, CA, USA), human transglutaminase 1 (B.C1) and human involucrin (rabbit polyclonal (both Biomedical Technologies, Stoughton,

MA, USA), human N-cadherin (GC4; Sigma-Aldrich, St. Louis, MO, USA), anti-pankeratin goat polyclonal, human α6-integrin (GoH3) and human HLA-ABC (G46-2.6) (all BD Biosciences Pharmingen), and human nuclei (235-1; Millipore, Billerica, MA, USA).

Fluorescence staining was investigated using a confocal laser scanning fluorescence microscope (Laser Scanning Confocal Imaging System MRC 1024; Bio-Rad, Richmond, CA, USA). Cells that stained positive to human (human nuclei or HLA-ABC) and keratinocyte markers were counted as positive for bone marrow-derived keratinocytes.

Statistical evaluation of results

Statistical analysis of differences in the means for each experimental group was carried out using the Student *t*-test, with significance set at $P < 0.05$.

Results

Human nuclei-positive and cytokeratin-positive cells are derived from human haematopoietic stem cells

No cells stained positively with antibodies against pankeratin, human CK5 or CK14, human transglutaminase I or human involucrin. Furthermore, culture of hHSCs in RPMI medium for 5 days did not result in any cells positive cells for any of these five antibodies. Spontaneous conversion of hHSCs to keratinocytes seldom happened.

Next, we investigated whether coculture with keratinocytes mediates hHSC differentiation into keratinocytes. Using a specific antibody against human nuclei,[13] we detected human nuclei+/cytokeratin+ cells (hNCs) after coculture of hHSCs and Pam 212 cells for 5 days (Fig. 1a). We also found human nuclei+/cytokeratin 14+ cells and human cytokeratin 5+ cells (Fig. 1b,c). These hNCs expressed HLA-ABC as a human origin marker (Fig. 1d). Furthermore, hNCs expressed human transglutaminase 1 and involucrin as other specific markers of keratinocytes (Fig. 1e). The number of hNCs increased relative to the coculture time, from 0.03 ± 0.002% at 6 h to 0.46 ± 0.11% at 48 h (Fig. 1f). However, coculture for 5 days did not introduce any colonies of hHSCs or hNCs.

Human haematopoietic stem cells cultured with fixed keratinocytes do not express keratinocyte markers

To determine whether the hNCs were generated through cell fusion or true differentiation, we examined whether multinucleate cells could result from cell fusionh between HSCs and keratinocytes.[14] Most hNCs were microscopically uninucleate, and only 0.1% of hNCs were binucleate, with human and nonhuman (presumed mouse) nuclei (Fig. 2a). To exclude the possibility of cell fusion at the initial hHSC to keratinocyte transition, hHSCs were cultured with 0.5% paraformaldehyde-fixed Pam 212 cells or NHEKs. It was predicted that the fixed cells would stabilize the cellular components, rendering live hHSCs resistant to fusion. This method has been shown to prevent fusion of live cells with fixed cells, while not disrupting receptor-mediated recognition and association of these cell types.[15] This procedure failed to convert hHSCs to hNCs (Fig. 2b), suggesting that hHSCs seldom fuse with keratinocytes and that the cell-surface molecules of keratinocytes do not induce hHSC differentiation into keratinocytes.

Human haematopoietic stem cells cultured with keratinocyte-conditioned media mediate their differentiation into keratinocytes

To clarify the potential role of the secretory factors released by keratinocytes, we treated hHSCs with the keratinocyte-conditioned medium from Pam 212 cells or NHEKs; interestingly, both types of medium induced hHSC conversion into keratinocytes (Fig. 2c). The number of hNCs in 10^4 hHSCs after 48 h in culture was 35 (0.35%) in NHEK-conditioned medium and 9 (0.09%) in Pam-212-conditioned medium (Table 1). The greater number in NHEK-conditioned medium compared with Pam-212-conditioned medium implies an association with species-specific factors. However, there were no significant difference between cultures with NHEK-conditioned medium and those with Pam-212-conditioned medium. Furthermore, 40 (0.40%) hNCs were detected in culture with fixed NHEK in NHEK-conditioned medium, and 29 (0.29%) in culture with fixed Pam 212 cells in Pam-212-conditioned medium. Fixed keratinocytes seemed to accelerate the conversion of hHSCs with keratinocyte-conditioned medium, but the difference was not significant. In addition, as control of cell type for the conditioned media, fibroblast-conditioned media never induced hHSCs to convert into keratinocytes.

To explore any additional effects of keratinocyte surface molecules on differentiation, we added blocking antibodies against keratinocyte surface molecules during culture. We chose human alpha 6-integrin and human N-cadherin as the surface molecules, as these molecules express on various stem cells, including



Figure 1 Coculture of human haematopoietic stem cells (hHSCs) and a mouse keratinocyte cell line, Pam212. (a) Expression of human nuclei (green) and cytokeratin (red) after 2 days in coculture, and cross-section analysis of the same cells (Z-axis). (b) Expression of human nuclei (green) and human cytokeratin 14 (red) after 2 days in coculture. (c) Expression of human cytokeratin 5 (green) and nuclei (propidium iodide staining, red) after 2 days in coculture. (d) Expression of human nuclei (green), human leucocyte antibody-ABC (red) and cytokeratin (blue). (e) Left: expression of human transglutaminase I (green) with transmission after 2 days in coculture; right: expression of involucrin (green) and human nuclei (red) with transmission after 2 days in coculture. (f) Percentages of hHSCs expressing keratin after 6, 12, 24 and 48 h in culture. $^{*}P < 0.05$ vs. 6 h.

epidermal stem cells, playing an important role in differentiation.[16,17] Blocking antibodies during coculture of hHSCs and fixed NHEK with NHEK-conditioned medium did not influence the keratinocyte conversion (data not shown).

It is possible that the humoral induction of keratinocyte differentiation is mediated by a specific growth factor such as KGF and IGF.[18] However, we did not observe hNCs with exposure of hHSCs to KGF or IGF, which are secreted exclusively from keratinocytes (data not shown). These findings suggest that soluble factors other than KGF and IGF in keratinocyte supernatant may mediate HSCs differentiation.

Discussion

We have shown that hHSCs differentiate into keratinocytes in the presence of factors secreted from keratinocytes, without cell fusion. In this study, hHSCs converted into keratinocytes when cocultured with keratinocytes. By contrast, hHSCs cocultured with fixed keratinocytes were found never to convert into

COLOR



Figure 2 Coculture of human haematopoietic stem cells (hHSCs) and Pam212 cells fixed with 0.5% paraformaldehyde, and culture of hHSCs in conditioned medium of Pam 212 cells. (a) Expression of human nuclei (green), mouse nuclei (blue) and cytokeratin (red) after 2 days in coculture of hHSCs and fixed Pam212 cells, and analysis of same cells by Z-axis or transmission. (b) Expression of human leucocyte antibody-ABC (green) and cytokeratin (red). (c) Expression of cytokeratin (blue) and human nuclei (green) in culture of hHSCs in the conditioned medium of Pam 212 cells.

Table 1 Frequency of cytokeratin-positive cells derived from human haematopoietic stem cells (hHSCs).

Treatment	CK-positive cells, *n**
Coculture with Pam 212 cells	49
Coculture with fixed Pam 212 cells	0
Coculture with mouse fibroblasts	0
Culture in Pam 212 CM	9
Culture with fixed Pam 212 in Pam-212 CM	29
Culture in NHEK CM	35
Culture with fixed NHEKs in NHEK CM	40

CK, cytokeratin; CM, conditioned medium; NHEK, normal human epidermal keratinocyte. *In 10^4 hHSCs.

keratinocytes, and hHSCs cultured with keratinocyte-conditioned medium expressed keratinocyte-specific markers. These data support the existence of factors secreted from keratinocytes or the existence of relatively paraformaldehyde-sensitive cell surface molecules that induce hHSCs to differentiate into keratinocytes.

We did not observe differentiation after exposure of hHSCs to the growth factors KGF or IGF, which suggests that other soluble factors might mediate HSC differentiation. Indeed, a previous report on hepatocyte differentiation showed that the specific growth factors hepatocyte growth factor and fibroblast growth factor

4 failed to mediate such conversion.[10] Further investigation is required to identify specific soluble factors that affect differentiation of HSCs to keratinocytes.

Recently Mortier *et al.*[19] succeeded in generating a skin equivalent model from human cord blood cells, which contains heterogeneous cells including hHSCs and MSCs. Although the origin of the induced keratinocytes was not investigated, we propose that most of these cells are mesenchyme-derived, as our observation showed that purified hHSCs seldom convert to keratinocytes.

Murine BMSCs can contribute to the regeneration of injured adult tissues of various organs, including brain, liver and heart tissue, after bone-marrow transplantation.[1,3,20] These unexpected events were initially attributed to BMSC transdifferentiation, supporting the emerging idea of extended plasticity of adult stem cells. The alternative hypothesis of spontaneous cell fusion has also been proposed as the primary cause of unexpected cell-fate switches of BMSCs into various cell lineages.[21,22]

We found that the number of fused multinucleate cells (which are unlikely to undergo further cell division) in the skin was very low. Conversely, Fujino *et al.*[23] reported the observation of fused functional hepatocytes after hHSC injection into immunodeficient mice. Taking these results into consideration, it is likely that both cell fusion and conversion from HSCs play some role in the repair of damaged tissue.

Previously, we reported that CTACK/CCL27 accelerates skin regeneration via accumulation of BMDCs.[7] Furthermore, bone-marrow transplantation improves type XVII collagen-knockout epidermolysis bullosa (EB) mice, in which the deficient type XVII collagen, a cutaneous structure protein produced by keratinocytes, was restored by BMSCs.[8] Because there have been ethical and safety concerns in using embryonic stem cells and induced pluripotent stem cells, therapies using HSCs are thought to be safer.[24] In the near future, stem cell therapies might be a candidate for the treatment of severe eEB, for which there is no effective treatment other than palliative care.[25]

Conclusion

When exposed to skin tissue, hHSCs are capable of taking on many characteristics of the skin cell types, and this is mediated by the plasma environment rather than by direct cell–cell interactions, including the specific gene and/or protein expression and function of the cells.

Learning points

- It is known that HSCs have the potential for conversion into keratinocytes.
- Several mechanisms, including direct cell–cell interaction between HSCs and damaged skin, and involvement of paracrine-regulated soluble factors from the organ have been speculated; however, there have been no reports identifying the precise mechanism involved.
- In this study, we found that the conversion of HSCs into keratinocytes is mediated by the plasma environment rather than by direct cell–cell interactions.

Acknowledgements

We are grateful to Ms Yuika Osaki for her excellent technical assistance. This work was supported in part by grants-in-aid for scientific research (No. 13357008 to HS and no. 15790563 to RA) and by the Project for Realization of Regenerative Medicine (to HS) from the Ministry of Education, Science, Sports and Culture of Japan and by the Health and Labor Sciences Research Grants (No. H13-Measures for Intractable Disease-02 HS) from the Ministry of Health, Labor and Welfare of Japan.

References

1 Jackson KA, Majka SM, Wang H *et al.* Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. *J Clin Invest* 2001; **107**: 1395–402.
2 Orlic D, Kajstura J, Chimenti S *et al.* Bone marrow cells regenerate infarcted myocardium. *Nature* 2001; **410**: 701–5.
3 LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. *Cell* 2002; **111**: 589–601.
4 Chang SA, Lee EJ, Kang HJ *et al.* Impact of myocardial infarct proteins and oscillating pressure on the differentiation of mesenchymal stem cells: effect of acute myocardial infarction on stem cell differentiation. *Stem Cells* 2008; **26**: 1901–12.
5 Dezawa M, Kanno H, Hoshino M *et al.* Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. *J Clin Invest* 2004; **113**: 1701–10.
6 Dezawa M, Ishikawa H, Hoshino M *et al.* Potential of bone marrow stromal cells in applications for neuro-degenera-

tive, neuro-traumatic and muscle degenerative diseases. *Curr Neuropharmacol* 2005; **3**: 257–66.
7 Inokuma D, Abe R, Fujita Y *et al.* CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes. *Stem Cells* 2006; **24**: 2810–6.
8 Fujita Y, Abe R, Inokuma D *et al.* Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice. *Proc Natl Acad Sci USA* 2010; **107**: 14345–50.
9 Sasaki M, Abe R, Fujita Y *et al.* Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. *J Immunol* 2008; **180**: 2581–7.
10 Jang YY, Collector MI, Baylin SB *et al.* Hematopoietic stem cells convert into liver cells within days without fusion. *Nat Cell Biol* 2004; **6**: 532–9.
11 Koizumi K, Sawada K, Sato N *et al.* Transitional changes in immunophenotypic subpopulations of human peripheral blood CD34+ cells expanded *in vitro*. *Exp Hematol* 1994; **22**: 1171–8.
12 Yamaguchi M, Sawada K, Sato N *et al.* A rapid nylon-fiber syringe system to deplete CD14+ cells for positive selection of human blood CD34+ cells. Use of immunomagnetic microspheres. *Bone Marrow Transplant* 1997; **19**: 373–9.
13 Uchida N, Buck DW, He D *et al.* Direct isolation of human central nervous system stem cells. *Proc Natl Acad Sci USA* 2000; **97**: 14720–5.
14 Johansson CB, Youssef S, Koleckar K *et al.* Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. *Nat Cell Biol* 2008; **10**: 575–83.
15 Devadas K, Hardegen NJ, Wahl LM *et al.* Mechanisms for macrophage-mediated HIV-1 induction. *J Immunol* 2004; **173**: 6735–44.
16 Tumbar T, Guasch G, Greco V *et al.* Defining the epithelial stem cell niche in skin. *Science* 2004; **303**: 359–63.
17 Zhang J, Niu C, Ye L *et al.* Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* 2003; **425**: 836–41.
18 Freedberg IM, Tomic-Canic M, Komine M *et al.* Keratins and the keratinocyte activation cycle. *J Invest Dermatol* 2001; **116**: 633–40.
19 Mortier L, Delesalle F, Formstecher P *et al.* Human umbilical cord blood cells form epidermis in the skin equivalent model. *Exp Dermatol* 2010; **19**: 929–30.
20 Zhang SC, Wernig M, Duncan ID *et al.* *In vitro* differentiation of transplantable neural precursors from human embryonic stem cells. *Nat Biotechnol* 2001; **19**: 1129–33.
21 Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. *Nature* 2003; **422**: 901–4.
22 Terada N, Hamazaki T, Oka M *et al.* Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. *Nature* 2002; **416**: 542–5.
23 Fujino H, Hiramatsu H, Tsuchiya A *et al.* Human cord blood CD34+ cells develop into hepatocytes in the livers of NOD/SCID/{gamma}cnull mice through cell fusion. *FASEB J* 2007; **21**: 3499–510.
24 Takahashi K, Tanabe K, Ohnuki M *et al.* Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861–72.
25 Wagner JE, Ishida-Yamamoto A, McGrath JA *et al.* Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. *N Engl J Med* 2010; **363**: 629–39.

Macrophage Migration Inhibitory Factor Is Essential for Eosinophil Recruitment in Allergen-Induced Skin Inflammation

Yoko Yoshihisa[1,3], Teruhiko Makino[1,3], Kenji Matsunaga[1], Ayumi Honda[2], Osamu Norisugi[1], Riichiro Abe[2], Hiroshi Shimizu[2] and Tadamichi Shimizu[1]

Macrophage migration inhibitory factor (MIF) is a pluripotent cytokine that has an essential role in the pathophysiology of experimental allergic inflammation. Recent findings suggest that MIF is involved in several allergic disorders, including atopic dermatitis (AD). In this study, the role of MIF in allergic skin inflammation was examined using a murine model of AD elicited by epicutaneous sensitization with ovalbumin (OVA). We observed the number of skin-infiltrating eosinophils to significantly increase in OVA-sensitized MIF transgenic (Tg) mice compared with their wild-type (WT) littermates. On the other hand, eosinophils were virtually absent from the skin of MIF knockout (KO) mice and failed to infiltrate their skin after repeated epicutaneous sensitization with OVA. The mRNA expression levels of eotaxin and IL-5 were significantly increased in OVA-sensitized skin sites of MIF Tg mice, but were significantly decreased in MIF KO mice in comparison with the levels in WT littermates. Eotaxin expression was induced by IL-4 stimulation in fibroblasts in MIF Tg mice, but not in MIF KO mice. These findings indicate that MIF can induce eosinophil accumulation in the skin. Therefore, the targeted inhibition of MIF might be a promising new therapeutic strategy for allergic skin diseases.

Journal of Investigative Dermatology (2011) **131,** 925–931; doi:10.1038/jid.2010.418; published online 30 December 2010

INTRODUCTION

Atopic dermatitis (AD) is a chronic, relapsing inflammatory disease of the skin with significant morbidity and an adverse impact on patient well-being (Morar *et al.*, 2006). AD is considered to result from a dysregulation of the normal interactions between the environment and genes, defects in skin barrier function, and systemic and local immunological responses (Leung *et al.*, 2004). The contribution of the immune response to the pathogenesis of AD has been attributed largely to abnormalities in adaptive immunity, with key roles being played by T-helper 1(Th1)/Th2 cell dysregulation, IgE production, dendritic cell signaling, and mast-cell hyperactivity, leading to the pruritic, inflammatory dermatosis that characterizes AD (Leung *et al.*, 2004). In addition, accumulation of eosinophils is characteristic of the inflammation associated with AD (Honma *et al.*, 2000).

Macrophage migration inhibitory factor (MIF) was the first lymphokine reported to prevent random migration of macrophages (Bloom and Bennett, 1966). As the molecular cloning of MIF complementary DNA (Weiser *et al.*, 1989), MIF has been re-evaluated as a proinflammatory cytokine and pituitary-derived hormone that potentiates endotoxemia (Bernhagen *et al.*, 1993; Bucala, 1996). MIF has an important role in delayed-type hypersensitivity (Bernhagen *et al.*, 1998). Recently, it has been demonstrated that MIF also upregulates the expression of Toll-like receptor-4, which mediates lipopolysaccharide binding and activation of macrophages (Roger *et al.*, 2001). MIF is now recognized as a cytokine that exhibits a broad range of immune and inflammatory activities, including induction of inflammatory cytokines, and regulation of macrophage and lymphocyte proliferation. Furthermore, MIF induces the endothelial expression of E-selectin, ICAM-1, vascular cell adhesion molecule-1, IL-8, and monocyte chemoattractant protein-1, thus resulting in leukocyte recruitment (Gregory *et al.*, 2004, 2006; Cheng *et al.*, 2010). MIF originates from multiple cellular sources such as activated T lymphocytes, monocytes, eosinophils, and keratinocytes (Rossi *et al.*, 1998; Shimizu *et al.*, 1999; Yamaguchi *et al.*, 2000). MIF has also been shown to

[1]*Department of Dermatology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama, Japan and* [2]*Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan*

[3]*These two authors contributed equally to this work.*

Correspondence: Teruhiko Makino or Tadamichi Shimizu, Department of Dermatology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama 930-0194, Japan.
E-mail: tmakino@med.u-toyama.ac.jp or shimizut@med.u-toyama.ac.jp

Abbreviations: AD, atopic dermatitis; KO, knockout; MIF, macrophage migration inhibitory factor; Tg, transgenic; WT, wild type

Received 9 September 2010; revised 2 November 2010; accepted 16 November 2010; published online 30 December 2010

exacerbate human allergic and inflammatory diseases, such as asthma (Rossi *et al.*, 1998) and acute respiratory distress syndrome (Donnelly *et al.*, 1997).

We recently reported excessive expression of MIF mRNA and protein in inflammatory skin lesions and in sera from AD patients (Shimizu *et al.*, 1999; Shimizu, 2005). We also showed that the serum MIF levels decrease as the clinical features of this disease improve, thus suggesting that MIF has a pivotal role in the inflammatory response in AD (Shimizu *et al.*, 1997). These studies raise the possibility that MIF is an important component of Th2-mediated immunopathology in general, and might therefore be relevant to chronic inflammatory allergic conditions.

Eosinophils may aggravate the inflammatory response in the skin of AD patients. Spergel *et al.* (1998, 1999) reported a murine model of allergic skin inflammation elicited by epicutaneous sensitization with ovalbumin (OVA). This model displays many of the features of human AD, including elevated total and specific IgE, dermatitis characterized by infiltration of the dermis by $CD4^+$ T cells and eosinophils, and increased local expression of mRNAs for the cytokines IL-4, IL-5, and IFN-γ. In our present study, MIF transgenic (Tg) mice and MIF knockout (KO) mice were used to assess the potential role of MIF in the pathogenesis of AD in this murine model of allergic skin inflammation. We also investigated the effects of MIF on eotaxin expression of dermal fibroblasts.



Figure 1. Expression of macrophage migration inhibitory factor (MIF) in tissues from MIF transgenic (Tg) mice. (**a**) Bone marrow (BM) and skin specimens were harvested from MIF Tg and wild-type (WT) mice, and the total RNA levels were determined by northern blot analysis as described in the Materials and Methods. The density of MIF bands was normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) signals. BM and skin from MIF Tg mice showed an ~10-fold higher level of MIF mRNA expression than those from WT mice. (**b**) Western blot analysis of skin from MIF Tg mice showed that the MIF protein level was also higher in MIF Tg mice than in WT mice.

RESULTS

The expression of MIF was increased in bone marrow and skin from MIF Tg mice

MIF Tg mice exhibited no lethal or prominent pathological lesions in the organs examined. A northern blot analysis revealed the MIF mRNA expression in bone marrow and skin from MIF Tg mice to be ~10 times higher than that in wild-type (WT) mice (Figure 1a). MIF protein was also increased in the skin from MIF Tg mice compared with that from WT mice, as demonstrated by western blotting (Figure 1b).

OVA-sensitized skin sites of MIF Tg mice showed marked eosinophil infiltration

To examine the role of MIF in eosinophilic infiltration, MIF Tg and WT mice were subjected to epicutaneous OVA sensitization. Only a few eosinophils were present in saline-sensitized skin from MIF Tg and WT mice, while eosinophilic infiltration of the dermis was significantly increased following epicutaneous sensitization with OVA. The mean number of eosinophils after OVA sensitization was 13.6 ± 2.84 in MIF Tg mice, but only 4.8 ± 1.37 in WT mice ($P<0.001$; Figure 2a). Figure 2b shows the histological features of OVA-sensitized skin sites in MIF Tg and WT mice. The epidermis was slightly thickened, and numerous eosinophils and mononuclear cells infiltrated the upper dermis around the vessels, in the OVA-sensitized skin of MIF Tg mice.

Eosinophil numbers were not increased in the OVA-sensitized skin of MIF KO mice

To further clarify the roles of MIF in eosinophilic infiltration, MIF KO mice were subjected to epicutaneous OVA sensitization. The mean number of eosinophils after OVA sensitization was 2.0 ± 0.94 in MIF KO mice, and did not differ from that after saline sensitization. Furthermore, this value was significantly lower than that of WT mice (4.8 ± 1.37, $P<0.05$; Figure 3a). Histological features also confirmed only a few eosinophils to be present in the dermis after OVA sensitization in MIF KO mice (Figure 3b).

The expression of eotaxin and Th2-type cytokines increased in the OVA-sensitized skin of MIF Tg mice, but decreased in the OVA-sensitized skin in MIF KO mice

We next examined the expression of mRNAs for eotaxin and cytokines in OVA-sensitized skin specimens from MIF Tg, MIF KO, and WT mice. The expression levels of eotaxin and Th2-type cytokines, especially IL-5, were increased in the OVA-sensitized skin of MIF Tg mice compared with WT mice. However, IFN-γ, a Th1-type cytokine, did not differ between MIF Tg and WT mice. Conversely, low eotaxin mRNA expression was observed in the OVA-sensitized skin of MIF KO mice compared with WT mice. Similarly, the mRNA expression of the Th2-type cytokines, including IL-4,



Figure 2. Eosinophil infiltration into ovalbumin (OVA)-sensitized skin sites of macrophage migration inhibitory factor (MIF) transgenic (Tg) mice. (**a**) The number of eosinophils in OVA-sensitized skin sites of MIF Tg mice was compared with the wild-type (WT) mice. Each value represents the mean ± SD ($n=5$; $^*P<0.001$, $^{**}P<0.0001$). (**b**) Histological features of OVA-sensitized skin sites in MIF Tg mice and WT mice. Scale bar for large panels = 50 μm; scale bar for small panels = 10 μm; hematoxylin and eosin section. Arrowheads point to eosinophils. The experiments were repeated three times and similar results were obtained.



Figure 3. Eosinophil infiltration induced in ovalbumin (OVA)-sensitized skin sites of macrophage migration inhibitory factor (MIF) knockout (KO) mice. (**a**) The number of eosinophils in OVA-sensitized skin sites of MIF KO mice was compared with wild-type (WT) mice. Each value represents the mean ± SD ($n=5$, $^*P<0.05$). (**b**) Histological features of OVA-sensitized skin sites in MIF KO and WT mice. Scale bar for large panels = 50 μm; scale bar for small panels = 10 μm; hematoxylin and eosin section. Arrowheads point to eosinophils. The experiments were repeated three times and similar results were obtained each time.

IL-5, and IL-13, were low in the OVA-sensitized skin of MIF KO mice compared with WT mice (Figure 4).

The expression and production of eotaxin in cultured fibroblasts from MIF Tg mice and from MIF KO mice

To clarify the role of MIF in the expression of eotaxin, we performed *in vitro* experiments. A previous report described that IL-4 could dose-dependently induce the expression of eotaxin mRNA in dermal fibroblasts from humans and mice (Mochizuki *et al.*, 1998). Using this protocol, we analyzed the eotaxin expression in cultured fibroblasts from MIF Tg, MIF KO, and WT mice by stimulating them with IL-4. Unstimulated fibroblasts from these mice barely expressed eotaxin mRNA. However, fibroblasts from MIF Tg mice showed dramatically increased eotaxin mRNA after stimulation with 5 ng ml^{-1} of IL-4 (Figure 5a). To evaluate whether there was an accompanying change in eotaxin protein production, the amount of eotaxin in fibroblast supernatants was also analyzed. Eotaxin proteins in the culture supernatant of fibroblasts from MIF Tg mice were also significantly increased compared with those from WT mice ($^*P<0.005$). However, fibroblasts from MIF KO mice showed minimal expression of eotaxin mRNA even when stimulated with 10 ng ml^{-1} of IL-4. Eotaxin production in the culture supernatant of fibroblasts from MIF KO mice was barely detectable (Figure 5b).

Recombinant MIF restored the expression and production of eotaxin in dermal fibroblasts from MIF KO mice

In dermal fibroblasts from WT mice, stimulation with IL-4 significantly induced the expression of eotaxin mRNA compared with unstimulated fibroblasts (Figure 6a). Addition of recombinant MIF significantly enhanced this increase in eotaxin expression. This suggests that the eotaxin expression in dermal fibroblasts from MIF Tg mice was markedly increased by IL-4 stimulation. A significant amount of eotaxin was also produced by combined stimulation with IL-4 ($^*P<0.005$, $^{**}P<0.05$; Figure 6b). Although the fibroblasts from MIF KO mice showed minimal induction of eotaxin mRNA expression in response to stimulation with IL-4, both the expression of eotaxin mRNA and the production of eotaxin protein were restored by addition of recombinant MIF



Figure 4. Expression levels of eotaxin and Th2-type cytokines in ovalbumin (OVA)-sensitized skin from macrophage migration inhibitory factor (MIF) transgenic (Tg) mice and MIF knockout (KO) mice. Reverse transcriptase-PCR analyses of eotaxin, IL-4, IL-5, IL-13, and IFN-γ levels in skin sites of MIF Tg and WT mice sensitized with OVA were performed. Eotaxin, IL-4, IL-5, and IL-13 mRNA expression levels were increased in OVA-sensitized MIF Tg; however, both eotaxin and Th2-type cytokines were markedly decreased in OVA-sensitized MIF KO mice, compared with WT mice. The experiments were repeated three times and similar results were obtained. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.



Figure 5. IL-4 induced eotaxin expression and production by fibroblasts from macrophage migration inhibitory factor (MIF) transgenic (Tg) and MIF knockout (KO) mice. Fibroblasts from MIF KO, MIF Tg, and wild-type (WT) mice were stimulated with IL-4 (5 or 10 ng ml^{-1}) for 24 hours. (**a**) RNA was extracted from the cells and the abundance of eotaxin mRNA was evaluated by reverse transcriptase-PCR. Data are from a representative experiment that was repeated three times and yielded similar results. (**b**) The eotaxin content of cultured supernatants was analyzed for eotaxin by ELISA. Each value represents the mean ± SD of five specimens. *$P<0.005$, **$P<0.05$. ND, not detected.

(Figure 6a and b). The levels of eotaxin production in MIF KO mouse fibroblasts exposed to MIF were similar to the levels in WT fibroblasts stimulated with IL-4 (Figure 6b).

DISCUSSION

There is growing evidence that the eosinophil is an important effecter cell in allergic inflammatory diseases, such as asthma and AD. Accumulation of eosinophils in the skin is characteristic of inflammation associated with AD (Leiferman, 1989; Kapp, 1995). This study explored, for the first time, the significant increase in eosinophil infiltration in the skin of MIF Tg mice after OVA sensitization, compared with WT mice. However, in MIF KO mice, eosinophils failed to infiltrate the skin after repeated epicutaneous sensitization with OVA. Eosinophils accumulate at inflammatory sites and release numerous mediators capable of initiating and maintaining allergic inflammation. Yamaguchi *et al.* (2000) reported eosinophils to be an important source of MIF in allergic inflammatory diseases. The number of eosinophils was reported to be significantly decreased in lung tissue and in bronchoalveolar lavage fluid from MIF KO mice after stimulation with OVA, compared with those from WT mice (Mizue *et al.*, 2005; Magalhães *et al.*, 2007; Wang *et al.*, 2009). In an allergic rhinitis model, eosinophil recruitment into the nasal submucosa was also suppressed in MIF KO mice (Nakamaru *et al.*, 2005). Consistent with these findings, our current evidence indicates that MIF is essential for the infiltration of eosinophils into the OVA-sensitized skin.

This study also demonstrated that the expression of both eotaxin and IL-5 is markedly increased in the OVA-sensitized



Figure 6. Recombinant macrophage migration inhibitory factor (MIF) restored eotaxin expression and production by IL-4 stimulation in dermal fibroblasts from MIF knockout (KO) mice. The fibroblasts were stimulated with IL-4 (10 ng ml^{-1}), MIF (100 ng ml^{-1}), or both IL-4 and MIF for 24 hours. (**a**) RNA was extracted from cells, and the abundance of eotaxin mRNA was evaluated by reverse transcriptase-PCR. Data are from a representative experiment that was repeated three times showing similar results. (**b**) The eotaxin contents of cultured supernatants were analyzed for eotaxin by ELISA. Each value represents the mean ± SD of six specimens. *$P<0.005$, **$P<0.05$. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ND, not detected.

skin sites of MIF Tg mice skin. The other Th2-type cytokines, IL-4 and IL-13, were also slightly increased in MIF Tg mice. On the other hand, the expression levels of eotaxin and Th2-type cytokines were markedly decreased in the OVA-sensitized skin sites of MIF KO mice. Acute AD involves a systemic Th2 response with eosinophilia, and marked infiltration of Th2 cells into skin lesions. These infiltrating T cells predominantly express IL-4, IL-5, and IL-13. Furthermore, the roles of cytokines in the induction of migration and the accumulation of eosinophils into an inflamed tissue have been extensively studied in recent years. Some of the important eosinophil chemoattractant cytokines include IL-5, IL-8, eotaxin, RANTES (regulated on activation, normal T cell expressed and secreted), and monocyte chemoattractant protein-3 (Lampinen *et al.*, 2004). Among these, eotaxin (CC chemokine ligand-11) is one of the most important eosinophil-selective chemoattractants (Jose *et al.*, 1994; Garcia-Zepeda *et al.*, 1996). Eotaxin is secreted by several cell types: epithelial cells, fibroblasts, and activated infiltrating leukocytes such as eosinophils (Garcia-Zepeda *et al.*, 1996; Ponath *et al.*, 1996; Uguccioni *et al.*, 1996). Eotaxin is reportedly related to the eosinophilia in allergic diseases, including AD and asthma (Ying *et al.*, 1997; Yawalkar *et al.*, 1999). IL-5 also has an important role in eosinophil development and differentiation (Sanderson, 1992). IL-5 KO mice had virtually no eosinophils in either saline-sensitized skin or in OVA-sensitized skin (Spergel *et al.*, 1999). Recently, Magalhães *et al.* (2009) reported that MIF was involved in IL-5-driven maturation of eosinophils and in tissue eosinophilia associated with *Schistosoma mansoni* infection. In addition, several earlier studies demonstrated that MIF KO mice failed to develop tissue eosinophilia, and that eotaxin, IL-4, and IL-5 were not induced in either allergic lung tissues or bronchoalveolar lavage fluid (Mizue *et al.*, 2005; Wang *et al.*, 2006). Accordingly, our results suggest that MIF is important in regulating both eotaxin and IL-5 in OVA-sensitized inflamed skin tissue.

In support of these *in vivo* observations, this study demonstrated that the expression of eotaxin was significantly increased after stimulation with IL-4 in fibroblasts from MIF Tg mice compared with WT fibroblasts, but not in fibroblasts from MIF KO mice. However, eotaxin expression in fibroblasts from MIF KO mice was restored by addition of recombinant MIF. These observations suggest that MIF is crucial to the expression of eotaxin, and antigen-induced eosinophil infiltration is suspected to be induced by eotaxin mainly by MIF, in addition with IL-5 production involved in MIF. Previous observations have shown that either IL-4 or IL-13 can increase eotaxin expression, and that they function synergistically with proinflammatory cytokines, such as tumor necrosis factor-α, to increase the production of eotaxin in epithelial cells and fibroblasts (Mochizuki *et al.*, 1998; Nakamura *et al.*, 1998; Li *et al.*, 1999; Stellato *et al.*, 1999; Fujisawa *et al.*, 2000; Terada *et al.*, 2000). Increases in both IL-4 and IL-13 in the inflamed skin of MIF Tg mice might involve enhancing the tissue eosinophilia. Furthermore, tumor necrosis factor-α secretion induced by MIF also has the ability to increase eotaxin expression in MIF Tg mice, on the basis of the known capacity of MIF to trigger the secretion of several inflammatory cytokines, including tumor necrosis factor-α (Donnelly *et al.*, 1997). It was recently elucidated that MIF activates an extracellular signal-regulated kinase-1/2–mitogen-activated protein kinase signaling through its receptor CD74 (Leng *et al.*, 2003) and c-Jun N-terminus kinase–mitogen-activated protein kinase signaling through CD74/CXCR4 (Lue *et al.*, 2011), in addition to the endocytic pathway described previously (Kleemann *et al.*, 2000); however, the receptor-mediated mechanism involved in MIF-mediated IL-4-induced eotaxin release is unclear. This mechanism should therefore be an important focus of research in association with MIF-mediated skin allergy.

Finally, we suggest that the inhibition of MIF might be an effective treatment for AD, suppressing both eosinophil infiltration and eotaxin expression in the skin. We recently demonstrated that in murine models of AD, MIF–DNA vaccination elicited the production of endogenous anti-MIF antibodies, producing rapid improvement of AD skin manifestations (Hamasaka *et al.*, 2009). Our previous data and the current findings therefore hold promise for the development of MIF inhibitors as a therapeutic strategy for allergic diseases.

MATERIALS AND METHODS

Materials

The following materials were obtained from commercial sources: a mouse eotaxin-specific ELISA kit from Genzyme TECHNE (Cambridge, MT); Isogen RNA extraction kit from Nippon Gene (Tokyo, Japan); M-MLV reverse transcriptase from GIBCO (Grand Island, NY); Taq DNA polymerase from Perkin-Elmer (Norwalk, CO); nylon membranes from Schleicher & Schuell (Keene, NH); Ficoll-Plaque Plus and Protein A Sepharose from Pharmacia (Uppsala, Sweden); recombinant mouse IL-4 from R&D systems (Minneapolis, MN). Recombinant rat MIF (this recombinant MIF crossreacts with that of mice) was expressed in *Escherichia coli* BL21/DE3 (Novagen, Madison, WI) and was purified as described previously (Shimizu *et al.*, 2004). All other chemicals were of analytical grade.

Mice

The MIF-overexpressing Tg mice were established after complementary DNA microinjection. Physical and biochemical characteristics, including body weight, blood pressure, and serum cholesterol and blood sugar levels, were normal, as reported previously (Sasaki *et al.*, 2004). The transgene expression was regulated by a hybrid promoter composed of the cytomegalovirus enhancer and the β-actin/β-globin promoter, as reported previously (Akagi *et al.*, 1997). The strain of the original MIF Tg mice was ICR, which were backcrossed with C57BL/6 for at least 10 generations. Tg mice were maintained by heterozygous sibling mating. Aged MIF Tg mice of 12 months or older developed neither skin allergies nor diseases. The MIF-deficient (KO) mice were established by targeted disruption of the *MIF* gene as described previously (Honma *et al.*, 2000), using a mouse strain bred onto a C57BL/6 background. MIF Tg, MIF KO, and WT mice were maintained under specific-pathogen-free conditions at the Institute for Animal Experiments of the Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama. All experiments were performed on 8-week-old female adult mice.

Epicutaneous sensitization

Epicutaneous sensitization of mice was performed as described previously (Spergel *et al.*, 1998). Briefly, each mouse was anesthetized with 10% nembutal (Hospira, Osaka, Japan), then shaved with a razor. One hundred mg of OVA (Sigma, St Louis, MO) in 100 μl of normal saline were placed on a 1 × 1 cm patch (Alcare, Tokyo, Japan), which was secured to the skin with a transparent bio-occlusive dressing (ALCARE). The patch was left in place for 1 week and then removed. At the end of the second week, an identical patch was reapplied to the same skin site. Each mouse had a total of three 1-week exposures to the patch, separated from each other by 2-week intervals. Inspection confirmed that the patch was still in place at the end of each sensitization period. Skin biopsies from treated areas were obtained for RNA isolation and histological evaluation. Six-micrometer thick skin sections were stained with hematoxylin and eosin (H&E). Eosinophils were counted under a microscope at a magnification of ×400 and expressed as the mean number of the cells in five random fields (one section per mouse, five mice per group).

Northern blot analysis

Bone marrow cells were isolated from the femurs of MIF Tg or WT mice, and 1×10^6 cells ml^{-1} was collected. Total RNA was isolated from bone marrow cells and skin from mice using an Isogen RNA extraction kit according to the manufacturer's protocols. Twenty μg of RNA from control and test samples were loaded onto a formaldehyde-agarose gel and the RNA was transferred onto a nylon membrane. RNA fragments obtained by restriction enzyme treatment for MIF and glyceraldehyde-3-phosphate dehydrogenase were labeled with [α-^{32}P]deoxycytidine triphosphate using a DNA random primer labeling kit (Enzo Life Sciences International, Farmingdale, NY). Hybridization was carried out at 42 °C for 24–48 hours. Post-hybridization washing was performed in 0.1% SDS with 0.2 × standard saline citrate (1 × standard saline citrate: 0.15 M NaCl, 0.015 M sodium citrate) at 65 °C for 15 minutes. The radioactive bands were visualized by autoradiography on Kodak X-AR5 film (Tokyo, Japan) and quantitatively analyzed using the NIH Image system (Bethesda, MD). The results were normalized by compensating for the glyceraldehyde-3-phosphate dehydrogenase mRNA levels.

Reverse transcription-PCR analysis

Total RNA was extracted from each mouse skin specimen. RNA reverse transcription was performed with M-MLV reverse transcriptase using random hexamer primers and subsequent amplification using Taq DNA polymerase. PCR was carried out for 35–40 cycles with denaturation at 94 °C for 30 seconds, annealing from 46 to 64 °C for 1 minute and extension at 72 °C for 45 seconds using a thermal cycler (PE Applied Biosystems Gene Amp PCR system 9700, Life Technologies Japan, Tokyo, Japan). The primers used in this study are described in Supplementary Table S1 online. After PCR, the amplified products were analyzed by 2% agarose gel electrophoresis.

Western blot analysis

The epidermis of each mouse was homogenized with a Polytron homogenizer (Kinematica, Lausanne, Switzerland). The protein concentrations of the cell homogenates were quantified using a Micro BCA protein assay reagent kit (Thermo Fisher Scientific, Yokohama, Japan). Equal amounts of homogenates were dissolved in 20 μl of Tris-HCL, 50 mM (pH 6.8), containing 2-mercaptoethanol (1%), SDS (2%), glycerol (20%) and bromophenol blue (0.04%), and then were heated to 100 °C for 5 minutes. The samples were then subjected to SDS–PAGE and electrophoretically transferred onto a nitrocellulose membrane. The membranes were blocked with 2.5% non-fat dry milk powder in phosphate-buffered saline, probed with antibodies against MIF (Shimizu *et al.*, 1996) and subsequently reacted with secondary IgG antibodies coupled with horseradish peroxidase. The resultant complexes were processed for the ECL detection system (Amersham Biosciences, Buckinghamshire, UK). The relative amounts of proteins associated with specific antibodies were normalized according to the intensities of β-actin (Sigma).

Cell culture

Skin specimens were obtained from the dorsal surfaces of newborn MIF Tg, MIF KO, and WT mice. The skin specimens were cut into 3–5 mm pieces and placed on a large Petri dish with the subcutaneous side down, followed by tissue incubation for 1 week in a humidified atmosphere of 5% CO_2 at 37 °C. Once sufficient numbers of fibroblasts had migrated out of the skin sections, pieces of the skin were removed and the cells were passaged by trypsin digestion in the same manner as wound-harvested fibroblasts. Fibroblasts were grown in DMEM containing 10% fetal calf serum and 1% penicillin/streptomycin. After 3 passages, the fibroblasts were used for the experiments. The fibroblasts from MIF KO and WT mice were stimulated with MIF (100 ng ml^{-1}), IL-4 (10 ng ml^{-1}), or MIF (100 ng ml^{-1}) in combination with IL-4 (10 ng ml^{-1}) for 24 hours. We also stimulated the fibroblasts from MIF Tg, MIF KO, and WT mice with IL-4 (5 or 10 ng ml^{-1}) alone for 24 hours. The cells were analyzed using reverse transcriptase-PCR. Culture supernatants were analyzed for eotaxin by ELISA.

Statistical analysis

Values are expressed as the means ± SD of the respective test or control group. The statistical significance of differences between the control and test groups was evaluated by either Student's *t*-test or one-way analysis of variance.

CONFLICT OF INTEREST

The authors state no conflict of interest.

ACKNOWLEDGMENTS

This research was supported by a Grant-in-Aid for Scientific Research (Nos.11670813 and 13357008) from the Japan Society for the Promotion of Science.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at http://www.nature.com/jid

REFERENCES

Akagi Y, Isaka Y, Akagi A *et al.* (1997) Transcriptional activation of a hybrid promoter composed of cytomegalovirus enhancer and beta-actin/beta-globin gene in glomerular epithelial cells *in vivo*. *Kidney Int* 51:1265–9

Bernhagen J, Calandra T, Bucala R (1998) Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. *J Mol Med* 76:151–61

Bernhagen J, Calandra T, Mitchell RA *et al.* (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. *Nature* 365:756–9

Bloom BR, Bennett B (1966) Mechanism of reaction *in vivo* associated with delayed-type hypersensitivity. *Science* 153:80–2

Bucala R (1996) MIF re-evaluated: pituitary hormone and glucocorticoid-induced regulator of cytokine production. *FASEB J* 7:19–24

Cheng Q, McKeown SJ, Santos L *et al.* (2010) Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. *J Immunol* 185:1238–47

Donnelly SC, Haslett C, Reid PT *et al.* (1997) Regulatory role for macrophage migration Inhibitory factor in acute respiratory distress syndrome. *Nat Med* 3:320–3

Fujisawa T, Kato Y, Atsuta J *et al.* (2000) Chemokine production by the BEAS-2B human bronchial epithelial cells: differential regulation of eotaxin, IL-8, and RANTES by TH2- and TH1-derived cytokines. *J Allergy Clin Immunol* 105:126–33

Garcia-Zepeda EA, Rothenberg ME, Ownbey RT *et al.* (1996) Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. *Nat Med* 2:449–56

Gregory JL, Leech MT, David JR *et al.* (2004) Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. *Arthritis Rheum* 50:3023–34

Gregory JL, Morand EF, McKeown SJ *et al.* (2006) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. *J Immunol* 177:8072–9

Hamasaka A, Abe R, Koyama Y *et al.* (2009) DNA vaccination against macrophage migration inhibitory factor improves atopic dermatitis in murine models. *J Allergy Clin Immunol* 124:90–9

Honma N, Koseki H, Akasaka T *et al.* (2000) Deficiency of the macrophage migration inhibitory factor gene has no significant effect on endotoxaemia. *Immunology* 100:84–90

Jose PJ, Griffiths-Johnson DA, Collins PD *et al.* (1994) Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. *J Exp Med* 179:881–7

Kapp A (1995) Atopic dermatitis-the skin manifestation of atopy. *Clin Exp Allergy* 25:210–9

Kleemann R, Hausser A, Geiger R *et al.* (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. *Nature* 408:211–6

Lampinen M, Carlson M, Hakansson LD *et al.* (2004) Cytokine-regulated accumulation of eosinophils in inflammatory disease. *Allergy* 59:793–805

Leiferman KM (1989) Eosinophils in atopic dermatitis. *Allergy* 44:20–6

Leng L, Metz CN, Fang Y *et al.* (2003) MIF signal transduction initiated by binding to CD74. *J Exp Med* 197:1467–76

Leung DY, Nicklas RA, Li JT *et al.* (2004) Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. *Ann Allergy Asthma Immunol* 93:S1–21

Li L, Xia Y, Nguyen A *et al.* (1999) Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. *J Immunol* 162:2477–87

Lue H, Dewor M, Leng L *et al.* (2011) Activation of the JNK signaling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. *Cell Signal* 23:135–44

Magalhães ES, Mourao-Sa DS, Vieira-de-Abreu A *et al.* (2007) Macrophage migration inhibitory factor is essential for allergic asthma but not for Th2 differentiation. *Eur J Immunol* 37:1097–106

Magalhães ES, Paiva CN, Souza HS *et al.* (2009) Macrophage migration inhibitory factor is critical to interleukin-5-driven eosinophilopoiesis and tissue eosinophilia triggered by Schistosoma mansoni infecton. *FASEB J* 23:1262–71

Mizue Y, Ghani S, Leng L *et al.* (2005) Role for macrophage migration inhibitory factor in asthma. *Proc Natl Acad Sci USA* 102:14410–5

Mochizuki M, Bartels J, Mallet AI *et al.* (1998) IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. *J Immunol* 160:60–8

Morar N, Willis-Owen SA, Moffatt MF *et al.* (2006) The genetics of atopic dermatitis. *J Allergy Clin Immunol* 118:24–34

Nakamaru Y, Oridate N, Nishihira J *et al.* (2005) Macrophage migration inhibitory factor (MIF) contributes to the development of allergic rhinitis. *Cytokine* 31:103–8

Nakamura H, Haley KJ, Nakamura T *et al.* (1998) Differential regulation of eotaxin expression by TNF-alpha and PMA in human monocytic U-937 cells. *Am J Physiol* 275:L601–10

Ponath PD, Qin S, Post TW *et al.* (1996) Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. *J Exp Med* 183:2437–48

Roger T, David J, Glauser MP *et al.* (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. *Nature* 414:920–4

Rossi AG, Haslett C, Hirani N *et al.* (1998) Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF): potential role in asthma. *J Clin Invest* 15:2869–74

Sanderson CJ (1992) Interleukin-5, eosinophils, and disease. *Blood* 79:3101–9

Sasaki S, Nishihira J, Ishibashi T *et al.* (2004) Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. *Kidney Int* 65:469–81

Shimizu T (2005) Role of macrophage migration inhibitory factor (MIF) in the skin. *J Dermatol Sci* 37:65–73

Shimizu T, Abe R, Ohkawara A *et al.* (1997) Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis. *Biochem Biophy Res Commun* 240:173–8

Shimizu T, Abe R, Ohkawara A *et al.* (1999) Increased production of macrophage migration inhibitory factor (MIF) by PBMCs of atopic dermatitis. *J Allergy Clin Immunol* 104:659–64

Shimizu T, Nishihira J, Watanabe H *et al.* (2004) Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor (MIF): its potential anti-inflammatory action. *Clin Exp Allergy* 34:103–9

Shimizu T, Ohkawara A, Nishihira J *et al.* (1996) Identification of macrophage migration inhibitory factor (MIF) in human skin and its immunohistochemical localization. *FEBS Lett* 381:188–202

Spergel JM, Mizoguchi E, Brewer JP *et al.* (1998) Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. *J Clin Invest* 101:1614–22

Spergel JM, Mizoguchi E, Oettgen H *et al.* (1999) Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. *J Clin Invest* 103:1103–11

Stellato C, Matsukura S, Fal A *et al.* (1999) Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and glucocorticoid budesonide. *J Immunol* 163:5624–32

Terada N, Hamano N, Nomura T *et al.* (2000) Interleukin-13 and tumor necrosis factor-a synergistically induce eotaxin production in human nasal fibroblasts. *Clin Exp Allergy* 20:348–55

Uguccioni M, Loetscher P, Forssmann U *et al.* (1996) Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. *J Exp Med* 183:2379–84

Wang B, Huang X, Wolters PJ *et al.* (2006) Cutting edge: deficiency of macrophage migration inhibitory factor impairs murine airway allergic responses. *J Immunol* 177:5779–84

Wang B, Zhang Z, Wang Y *et al.* (2009) Molecular cloning and characterization of macrophage migration inhibitory factor from small abalone Haliotis diversicolor supertexta. *Fish Shellfish Immunol* 27:57–64

Weiser WY, Temple PA, Witek-Giannotti JS *et al.* (1989) Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. *Proc Natl Acad Sci USA* 86:7522–6

Yamaguchi E, Nishihira J, Shimizu T *et al.* (2000) Macrophage migration inhibitory factor (MIF) in bronchial asthma. *Clin Exp Allergy* 30:1244–9

Yawalkar N, Uguccioni M, Schärer J *et al.* (1999) Enhanced expression of eotaxin and CCR3 in atopic dermatitis. *J invest Dermatol* 113:43–8

Ying S, Robinson DS, Meng Q *et al.* (1997) Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic athma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. *Eur J Immunol* 27:3507–16

xeroderma pigmentosum skin *in vitro*: a model to study hypersensitivity to UV light. *Photochem Photobiol* 81:19–24

Epp N, Fürstenberger G, Müller K *et al.* (2007) 12R-lipoxygenase deficiency disrupts epidermal barrier function. *J Cell Biol* 177:173–82

Gache Y, Baldeschi C, Del RM *et al.* (2004) Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. *Hum Gene Ther* 15:921–33

García M, Larcher F, Hickerson RP *et al.* (2011) Development of skin-humanized mouse models of pachyonychia congenita. *J Invest Dermatol* 131:1053–60

Green H (1978) Cyclic AMP in relation to proliferation of the epidermal cell: a new view. *Cell* 15:801–11

Lampert IA (1985) Expression of class II MHC antigen on epithelia and autoimmunity. *Lancet* 2:1078

Leigh I, Watt F (1994) *Keratinocyte Methods.* Cambridge: Cambridge University Press

Mildner M, Ballaun C, Stichenwirth M *et al.* (2006) Gene silencing in a human organotypic skin model. *Biochem Biophys Res Commun* 348:76–82

Mildner M, Jin J, Eckhart L *et al.* (2010) Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. *J Invest Dermatol* 130:2286–94

O'Shaughnessy RF, Choudhary I, Harper JI (2010) Interleukin-1 alpha blockade prevents hyperkeratosis in an *in vitro* model of lamellar ichthyosis. *Hum Mol Genet* 19:2594–605

Oji V, Eckl KM, Aufenvenne K *et al.* (2010) Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. *Am J Hum Genet* 87:274–81

Rheinwald JG, Green H (1975) Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. *Cell* 6:331–43

Schäfer-Korting M, Bock U, Diembeck W *et al.* (2008) The use of reconstructed human epidermis for skin absorption testing: results of the validation study. *Altern Lab Anim* 36:161–87

Thomas AC, Tattersall D, Norgett EE *et al.* (2009) Premature terminal differentiation and a reduction in specific proteases associated with loss of ABCA12 in Harlequin ichthyosis. *Am J Pathol* 174:970–8

Tjabringa G, Bergers M, van Rens D *et al.* (2008) Development and validation of human psoriatic skin equivalents. *Am J Pathol* 173: 815–23

Williams ML (1992) Ichthyosis: mechanisms of disease. *Pediatr Dermatol* 9:365–8

AKT Has an Anti-Apoptotic Role in ABCA12-Deficient Keratinocytes

Journal of Investigative Dermatology (2011) **131,** 1942–1945; doi:10.1038/jid.2011.132; published online 2 June 2011

TO THE EDITOR

Harlequin ichthyosis (HI) is a hereditary skin disorder characterized by severe hyperkeratosis and impaired skin barrier function (Moskowitz *et al.*, 2004; Akiyama *et al.*, 2005). We have identified the ATP-binding cassette transporter A12 (*ABCA12*) as the causative gene of HI and, furthermore, demonstrated that ABCA12 is essential for keratinocyte lipid transport (Akiyama *et al.*, 2005; Yanagi *et al.*, 2008). Loss of ABCA12 function causes lipid transport to be defective in keratinocytes of the upper spinous and granular layers, resulting in the deposition of numerous intracellular lipid droplets and malformation of intercellular lipid layers (Akiyama *et al.*, 2005; Yanagi *et al.*, 2010). Recently, we have shown that gangliosides accumulate in the differentiated keratinocytes of HI patients (Mitsutake *et al.*, 2010). On the basis of the evidence that lipid accumulation is involved in keratinocyte apoptosis (Wang *et al.*, 2001; Uchida *et al.*, 2010), we investigated apoptotic and anti-apoptotic parameters in skin samples from HI patients and *Abca12*$^{-/-}$ HI model mice.

We studied the skin of two HI patients and that of *Abca12*$^{-/-}$ mice. The *ABCA12* mutations of the two HI patients have been previously reported: one patient has the homozygous splice acceptor site mutation c.3295-2A>G and the other has the homozygous nonsense mutation p.Arg434X (Akiyama *et al.*, 2005). The procedure for generating *Abca12*$^{-/-}$ mice, the establishment of primary-cultured keratinocytes, immunofluorescence staining, immunoblotting, and real-time reverse transcriptase PCR analysis has been previously described (Yanagi *et al.*, 2008, 2010). First, we investigated the apoptosis of HI patient epidermis by hematoxylin–eosin stain and TUNEL assay (*In situ* Apoptosis Detection Kit, Takara Bio, Otsu, Japan). In the HI patients, the nuclei of the granular-layer keratinocytes were condensed (Figure 1b) and they show positive for TUNEL labeling (Figure 1d), although apoptotic nuclei are rare in the normal human epidermis (Figure 1a, c). The histopathological findings and results of TUNEL staining of the *Abca12*$^{-/-}$ mice were similar to those in the skin of the HI patients (Figure 1f and h). TUNEL staining in the epidermis of 18.5-day embryos indicated that the apoptosis of keratinocytes started during fetal skin development (Figure 1j).

We assessed the degree of AKT activation of *Abca12*$^{-/-}$ skin and keratinocytes using anti-AKT antibody #4691 and anti-phosphorylated AKT (Ser473) #4060 antibody (Cell Signaling, Danvers, MA). By immunoblot analysis, differentiated primary-cultured keratinocytes and the epidermis of *Abca12*$^{-/-}$ mice showed higher expression levels of Ser-473 phosphorylated AKT than those of the control wild-type mice (Figure 1o). Immunofluorescence staining detected phosphorylated AKT in the upper granular-layer keratinocytes of the *Abca12*$^{-/-}$ mouse skin (Figure 1l), but not in the skin of control wild-type mouse (Figure 1k). Cell proliferation was assessed by Ki-67 immunofluorescence (Figure 1). Ki-67 stain was similar in the wild-type and the *Abca12*$^{-/-}$ samples, indicating that the granular-layer keratinocytes of the *Abca12*$^{-/-}$ neonatal mice showed no excessive cell proliferation. To clarify whether AKT activation has

Abbreviations: ABCA12, ATP-binding cassette transporter A12; HI, harlequin ichthyosis; PPAR, peroxisome proliferator-activated receptor; RXR, retinoid X receptor

anti-apoptotic effects on *Abca12*$^{-/-}$ keratinocytes, we performed TUNEL staining of keratinocytes treated with AKT inhibitor, which blocks AKT phosphorylation (#124017; InSolution Akt Inhibitor VIII, Calbiochem, San Diego, CA). *Abca12*$^{-/-}$ keratinocytes incubated with 10 μM #124017 AKT inhibitor showed a notably greater number of TUNEL-positive cells than both wild-type keratinocytes with AKT inhibitor and *Abca12*$^{-/-}$ keratinocytes without AKT inhibitor (Figure 2). These results suggest that AKT activation helps *Abca12*$^{-/-}$ keratinocytes to avoid apoptosis. Furthermore, mRNA and protein levels of peroxisome proliferator-activated receptor (PPAR)-δ from *Abca12*$^{-/-}$ epidermis were shown to be significantly higher than those from wild-type epidermis (Taqman Gene Expression Assay, probe ID, Mm00803184_m1, Mm99999915_g1, Applied Biosystems, Carlsbad, CA; anti-PPAR-δ antibody H-74, Santa Cruz, Santa Cruz, CA; Supplementary Figure S1 online), which suggests upregulation of PPAR-δ as a candidate pathway for AKT activation.

Herein, we have suggested that apoptosis is involved in the pathomechanism of HI. Defective lipid transport due to loss of ABCA12 function leads to the accumulation of intracellular lipids, including glucosylceramides and gangliosides (Akiyama *et al.*, 2005; Mitsutake *et al.*, 2010). Studies by Wang *et al.* (2001) and Sun *et al.* (2002) showed that the elevation of ganglioside levels leads to keratinocyte apoptosis. Thus, we are able to speculate that the accumulation of gangliosides leads to the apoptosis of *Abca12*$^{-/-}$ keratinocytes, although the exact mechanism of apoptosis in *Abca12*$^{-/-}$ keratinocytes remains unclear.



Figure 1. ATP-binding cassette transporter A12-deficient keratinocytes show TUNEL-positive nuclei and AKT activation. (**a–d**) In the harlequin ichthyosis patients, the nuclei of the granular-layer keratinocytes are condensed (**b**, white arrows) and they show positive TUNEL labeling (**d**, white arrows), although apoptotic nuclei are rare in the normal human epidermis (**a**, **c**). Data shown are representative of those from the two harlequin ichthyosis patients. (**e**, **f**) Granular-layer keratinocytes of *Abca12*$^{-/-}$ mice show more condensed nuclei (**f**, white arrows) than those of wild-type mice (**e**). (**g–j**) Granular-layer keratinocytes of *Abca12*$^{-/-}$ mice, a neonate (**h**) and an 18.5-day embryo (**j**), show TUNEL-positive nuclei. No TUNEL-positive cells are seen in the epidermis of the control wild-type mice (**g**, **i**). Dotted lines indicate the basement membrane. Nonspecific staining is seen on the skin surface (white arrowheads). (**k**, **l**) By immunofluorescence staining, AKT activation (Ser-473 phosphorylated AKT; green) is observed in granular-layer keratinocytes of *Abca12*$^{-/-}$ mice. (**m**, **n**) Immunofluorescence staining for the Ki-67-proliferation marker shows similar staining patterns of basal keratinocytes in wild-type (**m**) and *Abca12*$^{-/-}$ (**n**) samples. (**a**, **b**, **e**, **f**; hematoxylin–eosin (H–E) stain. Bars of **c**, **d**, **g**, **h**, **i**, **j**, **k**, **l**, **m**, **n** = 20 μm. Bars of **a**, **b**, **e**, **f** = 5 μm.) (**o**) Immunoblot analysis shows that levels of serine-473-phosphorylated AKT (pAKT) in neonatal epidermis and differentiated keratinocytes of *Abca12*$^{-/-}$ mice are higher than those of wild-type mice.



Figure 2. Inhibition of AKT activation leads to apoptosis of *Abca12*$^{-/-}$ keratinocytes. (**a**) Immunoblot analysis indicates that the AKT inhibitor can inhibit AKT activation (phosphorylated AKT (pAKT) synthesis) in differentiated keratinocytes. (**b–e**) TUNEL staining of keratinocytes cultured under high Ca^{2+} condition treated with/without the AKT inhibitor. Neither wild-type cells (**b**) nor *Abca12*$^{-/-}$ cells (**c**) are TUNEL positive. *Abca12*$^{-/-}$ keratinocytes with the AKT inhibitor (#124017; 10 μM) show many TUNEL-positive nuclei (**e**), although only a small number of wild-type cells with the AKT inhibitor are TUNEL positive (**d**). (Bars = 20 μm.) (**f**) Percentage of TUNEL-positive keratinocytes. *Abca12*$^{-/-}$ keratinocytes with AKT inhibitor shows a significantly greater number of TUNEL-positive nuclei than wild-type keratinocytes with/without the AKT inhibitor and *Abca12*$^{-/-}$ keratinocytes without the AKT inhibitor. ($n = 3$, mean ± SD, $^*P < 0.05$).

Although *Abca12*$^{-/-}$ granular-layer keratinocytes show characteristics of apoptosis, including condensed nuclei and positive TUNEL labeling, they are able to form epidermal stratification. In several disorders involving keratinocyte apoptosis, e.g., toxic epidermal necrolysis, the apoptotic epidermal keratinocytes show not only TUNEL-positive nuclei but also defective epidermal stratification (Abe *et al.*, 2003). Thrash *et al.* (2006) reported that AKT1 activation is an essential signal for keratinocyte cell survival and stratification, by experiments with gene silencing and three-dimensional cell cultures. Thus, we hypothesized that the AKT pathway might work as a compensatory mechanism against apoptosis in *Abca12*$^{-/-}$ keratinocytes. We have clearly shown that AKT activation occurs in *Abca12*$^{-/-}$ granular-layer keratinocytes, which suggests that AKT activation serves to prevent the cell death of *Abca12*$^{-/-}$ keratinocytes. By immunoblot analysis using anti-AKT1/2/3 antibodies (#2938/3063/3788, Cell Signaling), *Abca12*$^{-/-}$ epidermis showed expression of AKT1 and AKT2, but not AKT3 (Supplementary Figure S2 online). Compared with wild-type epidermis, *Abca12*$^{-/-}$ epidermis seemed to have more AKT1 than AKT2. From our data and the literature (Thrash *et al.*, 2006), we are able to speculate that AKT1 is the major isoform of phosphorylated AKT in *Abca12*$^{-/-}$ epidermis.

We have shown that PPAR-δ is a candidate molecule in the upstream of the AKT activation pathway in *Abca12*$^{-/-}$ keratinocytes. Di-Poi *et al.* (2002) reported that PPAR-δ has an anti-apoptotic role in keratinocytes via transcriptional control of the AKT1 signaling pathway. PPAR-δ also regulates the expression of ABCA12 (Jiang *et al.*, 2008). From these studies, we can speculate that upregulation of PPAR-δ is in response to apoptosis or decreased ABCA12 expression. To ascertain the function of PPAR-δ, we performed the experiments using a PPAR-δ-specific antagonist (GSK0660, Santa Cruz). Differentiated *Abca12*$^{-/-}$ keratinocytes treated with 1 μM GSK0660 for 48 hours showed TUNEL-positive nuclei, from which we are able to speculate an anti-apoptotic role for